On October 29, 2018 Dynavax Technologies Corporation (NASDAQ: DVAX) reported that it will report financial results for the third quarter ended September 30, 2018 after market close on Monday, November 5, 2018, and host a conference call that day to review the results and provide an update on the launch of HEPLISAV-B [Hepatitis B Vaccine, (Recombinant) Adjuvanted] and its SD-101 immuno-oncology program at 4:30pm ET/1:30pm PT (Press release, Dynavax Technologies, OCT 29, 2018, View Source [SID1234530326]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

To access the call, participants must dial (866) 420-4066 in the U.S. or (409) 217-8237 internationally, and use the conference ID 5179228. The live call will be webcast and can be accessed in the "Investors and Media" section of the company’s website at www.dynavax.com. A replay of the webcast will be available for 30 days following the live event.